Cited by 1,967Cancer-related Molecular PathwaysCell death mechanisms and regulationPI3K/AKT/mTOR signaling in cancer

The DOI matches its Crossref record; 168 of the 169 references it cites were found in a registry or an index.

The first 30 years of p53: growing ever more complex.

Open access

Levine, Arnold J., Oren, Moshe·2009·Nature Reviews Cancer

Open this paper in CoChat — free account

Abstract

Thirty years ago p53 was discovered as a cellular partner of simian virus 40 large T-antigen, the oncoprotein of this tumour virus. The first decade of p53 research saw the cloning of p53 DNA and the realization that p53 is not an oncogene but a tumour suppressor that is very frequently mutated in human cancer. In the second decade of research, the function of p53 was uncovered: it is a transcription factor induced by stress, which can promote cell cycle arrest, apoptosis and senescence. In the third decade after its discovery new functions of this protein were revealed, including the regulation of metabolic pathways and cytokines that are required for embryo implantation. The fourth decade of research may see new p53-based drugs to treat cancer. What is next is anybody's guess.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nrc2723

Cites

168 of 168 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“More recently, induction of cellular senescence was identified as an additional mechanism whereby p53 curbs neoplastic processe”
p53, guardian of the genome
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
The retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Self-citation
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
Self-citation
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765

Flagged first, then by citations

Show all 169 references

1 of the 169 references couldn’t be matched to a known paper.

Sorted by citations

Items 401–500 of 1,002

Cyclin-Dependent Kinase Activity Controls the Onset of the HCMV Lytic Cycle
Zydek, M., Hagemeier, C., & Wiebusch, L. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1001096 · Cited by 55
lncRNA TUG1 as a ceRNA promotes PM exposure-induced airway hyper-reactivity
Li, B., Huang, N., Wei, S., Xv, J., Meng, Q., Aschner, M., Li, X., & Chen, R. (2021) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2021.125878 · Cited by 53
Chemotherapy and mismatch repair deficiency cooperate to fuel TP53 mutagenesis and ALL relapse
Yang, F., Brady, S. W., Tang, C. S., Sun, H., Du, L., Barz, M., Ma, X., Chen, Y., Fang, H., Li, X., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00230-8 · Cited by 55
Deubiquitinating enzyme regulation of the p53 pathway: A lesson from Otub1
Sun, X. (2014) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v5.i2.75 · Cited by 56
TPL2 kinase is a suppressor of lung carcinogenesis
Gkirtzimanaki, K., Gkouskou, K. K., Oleksiewicz, U., Nikolaidis, G., Vyrla, D., Liontos, M., Pelekanou, V., Kanellis, D. C., Evangelou, K., Stathopoulos, E. N., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215938110 · Cited by 54
p53 orchestrates between normal differentiation and cancer
Rivlin, N., Koifman, G., & Rotter, V. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.12.006 · Cited by 56
Tumor suppression in skin and other tissues via cross-talk between vitamin D- and p53-signaling
Reichrath, J., Reichrath, S., Heyne, K., VOGT, T. M., & Roemer, K. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00166 · Cited by 53
Zinc supplementation augments in vivo antitumor effect of chemotherapy by restoring p53 function
Margalit, O., Simon, A. J., Yakubov, E., Puca, R., Yosepovich, A., Avivi, C., Jacob‐Hirsch, J., Gelernter, I., Harmelin, A., Barshack, I., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26441 · Cited by 58
Progress and prospects of circular RNAs in Hepatocellular carcinoma: Novel insights into their function
Hu, J., Peng, L., Song, Y., Ge, Y., Meng, X., Huang, C., Li, J., & Xu, T. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26154 · Cited by 54
Mutations in BRCA1, BRCA2 and other breast and ovarian cancer susceptibility genes in Central and South American populations
Lilian Jara, S., Morales, S., de Mayo, T., González‐Hormazábal, P., Carrasco, V., & Godoy, R. (2017) · Biological Research · doi:10.1186/s40659-017-0139-2 · Cited by 57
Signal transduction pathways and resistance to targeted therapies in glioma
Tomiyama, A., & Ichimura, K. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.01.004 · Cited by 54
Deciphering the Mounting Complexity of the p53 Regulatory Network in Correlation to Long Non-Coding RNAs (lncRNAs) in Ovarian Cancer
Pal, S., Garg, M., & Pandey, A. K. (2020) · Cells · doi:10.3390/cells9030527 · Cited by 54
The mTOR pathway negatively controls ATM by up-regulating miRNAs
Shen, C., & Houghton, P. J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1220898110 · Cited by 50
The Challenges and Prospects of p53-Based Therapies in Ovarian Cancer
Wallis, B., Bowman, K. E. R., Lu, P., & Lim, C. S. (2023) · Biomolecules · doi:10.3390/biom13010159 · Cited by 58
p53‐dependent transcriptional regulation of EDA2R and its involvement in chemotherapy‐induced hair loss
Brosh, R., Sarig, R., Natan, E. B., Molchadsky, A., Madar, S., Bornstein, C., Buganim, Y., Shapira, T., Goldfinger, N., Paus, R., et al. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.04.058 · Cited by 53
The nucleoside analog clitocine is a potent and efficacious readthrough agent
Friesen, W. J., Trotta, C. R., Tomizawa, Y., Zhuo, J., Johnson, B., Sierra, J., Roy, B., Weetall, M. L., Hedrick, J., Sheedy, J., et al. (2017) · RNA · doi:10.1261/rna.060236.116 · Cited by 54
The effect of resveratrol, its naturally occurring derivatives and tannic acid on the induction of cell cycle arrest and apoptosis in rat C6 and human T98G glioma cell lines
Zielińska‐Przyjemska, M., Kaczmarek, M., Krajka‐Kuźniak, V., Łuczak, M. W., & Baer‐Dubowska, W. (2017) · Toxicology in Vitro · doi:10.1016/j.tiv.2017.06.004 · Cited by 53
CDK16 Phosphorylates and Degrades p53 to Promote Radioresistance and Predicts Prognosis in Lung Cancer
Xie, J., Li, Y., Jiang, K., Hu, K., Zhang, S., Dong, X., Dai, X., Liu, L., Zhang, T., Yang, K., et al. (2017) · Theranostics · doi:10.7150/thno.21963 · Cited by 52
Loss of p53 suppresses replication-stress-induced DNA breakage in G1/S checkpoint deficient cells
Benedict, B., van Harn, T., Dekker, M., Hermsen, S., Küçükosmanoğlu, A., Pieters, W., Delzenne‐Goette, E., Dorsman, J. C., Petermann, E., Foijer, F., et al. (2018) · eLife · doi:10.7554/elife.37868 · Cited by 54
p53 induces ARTS to promote mitochondrial apoptosis
Hao, Q., Chen, J., Liao, J., Huang, Y., Gan, Y., Larisch, S., Zeng, S. X., Lu, H., & Zhou, X. Y. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03463-8 · Cited by 53
Rescue of embryonic stem cells from cellular transformation by proteomic stabilization of mutant p53 and conversion into WT conformation
Rivlin, N., Katz, S., Doody, M., Sheffer, M., Horesh, S., Molchadsky, A., Koifman, G., Shetzer, Y., Goldfinger, N., Rotter, V., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320428111 · Cited by 52
Life or death
Schlereth, K., Charles, J. P., Bretz, A. C., & Stiewe, T. (2010) · Cell Cycle · doi:10.4161/cc.9.20.13595 · Cited by 54
TNFα-Induced Apoptosis Enabled by CCN1/CYR61: Pathways of Reactive Oxygen Species Generation and Cytochrome c Release
Juric, V., Chen, C.-C., & Lau, L. F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031303 · Cited by 52
KAISO, a critical regulator of p53-mediated transcription of CDKN1A and apoptotic genes
Koh, D.-I., Han, D., Ryu, H., Choi, W., Jeon, B.-N., Kim, M.-K., Kim, Y., Kim, J. Y., Parry, L., Clarke, A. R., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318780111 · Cited by 52
Mutant p53 induces EZH2 expression and promotes epithelial-mesenchymal transition by disrupting p68-Drosha complex assembly and attenuating miR-26a processing
Jiang, F., He, Y., Wang, H. H., Zhang, H., Zhang, J., Yan, X., Wang, X.-J., Che, Q., Ke, J., Chen, Z., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6350 · Cited by 52
p53 functional deficiency in human colon cancer cells promotes fibroblast-mediated angiogenesis and tumor growth
Hayashi, Y., Tsujii, M., Kodama, T., Akasaka, T., Kondo, J., Hikita, H., Inoue, T., Tsujii, Y., Maekawa, A., Yoshii, S., et al. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw085 · Cited by 51
Targeting Oncogenic Pathways in the Era of Personalized Oncology: A Systemic Analysis Reveals Highly Mutated Signaling Pathways in Cancer Patients and Potential Therapeutic Targets
Karagiannakos, A., Adamaki, M., Tsintarakis, A., Vojtěšek, B., Fåhræus, R., Zoumpourlis, V. C., & Karakostis, K. (2022) · Cancers · doi:10.3390/cancers14030664 · Cited by 59
Recent advances in microfluidic methods in cancer liquid biopsy
Iliescu, F. S., Poenar, D. P., Yu, F., Ni, M., Chan, K. H., Cima, I., Taylor, H. K., Cima, I., & Iliescu, C. (2019) · Biomicrofluidics · doi:10.1063/1.5087690 · Cited by 51
VRK1 interacts with p53 forming a basal complex that is activated by UV‐induced DNA damage
López-Sánchez, I., Valbuena, A., Vázquez-Cedeira, M., Khadake, J., Sanz-García, M., Carrillo-Jiménez, A., & Lazo, P. A. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.01.040 · Cited by 52
Identification of Two Reactive Cysteine Residues in the Tumor Suppressor Protein p53 Using Top-Down FTICR Mass Spectrometry
Scotcher, J., Clarke, D. J., Weidt, S. K., Mackay, C. L., Hupp, T. R., Sadler, P. J., & Langridge‐Smith, P. R. R. (2011) · Journal of the American Society for Mass Spectrometry · doi:10.1007/s13361-011-0088-x · Cited by 51
Hypoxia drives apoptosis independently of p53 and metallothionein transcript levels in hemocytes of the whiteleg shrimp Litopenaeus vannamei
Félix-Portillo, M., Martínez-Quintana, J. A., Arenas-Padilla, M., Mata‐Haro, V., Gómez‐Jiménez, S., & Yepiz-Plascencia, G. M. (2016) · Chemosphere · doi:10.1016/j.chemosphere.2016.07.041 · Cited by 51
To Eat and to Be Eaten: Mutual Metabolic Adaptations of Immune Cells and Intracellular Bacterial Pathogens upon Infection
Eisenreich, W., Rudel, T., Heesemann, J., & Goebel, W. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00316 · Cited by 53
p53-dependent expression of CXCR5 chemokine receptor in MCF-7 breast cancer cells
Mitkin, N. A., Hook, C., Schwartz, A. M., Biswas, S., Кочетков, Д. В., Muratova, A. M., Afanasyeva, M., Kravchenko, J. E., Bhattacharyya, A., & Kuprash, D. V. (2015) · Scientific Reports · doi:10.1038/srep09330 · Cited by 49
Emerging Roles of MicroRNA-22 in Human Disease and Normal Physiology
Xiong, J. (2012) · Current Molecular Medicine · doi:10.2174/156652412799218886 · Cited by 49
Vascular Endothelial Growth Factor Acts Primarily via Platelet-Derived Growth Factor Receptor α to Promote Proliferative Vitreoretinopathy
Pennock, S., Haddock, L. J., Mukai, S., & Kazlauskas, A. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.07.026 · Cited by 50
Caspase-2 impacts lung tumorigenesis and chemotherapy response in vivo
Terry, M. R., Arya, R. S., Mukhopadhyay, A., Berrett, K., Clair, P. M., Witt, B. L., Salama, M. E., Bhutkar, A. J., & Oliver, T. G. (2014) · Cell Death and Differentiation · doi:10.1038/cdd.2014.159 · Cited by 49
Activation of Erk and p53 regulates copper oxide nanoparticle-induced cytotoxicity in keratinocytes and fibroblasts
Luo, C. Y., Li, Y., Yang, L., Long, J., Zheng, Y., Liu, J., Xiao, S., & Jia, J. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s67688 · Cited by 51
Long story short: p53 mediates innate immunity
Miciak, J. J., & Bunz, F. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.03.001 · Cited by 49
MicroRNA-141-3p promotes glioma cell growth and temozolomide resistance by directly targeting p53
Zhou, X., Wu, W., Zeng, A., Nie, E., Jin, X., Yu, T., Zhi, T., Jiang, K., Wang, Y., Zhang, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.20528 · Cited by 51
Combined Inactivation of TP53 and MIR34A Promotes Colorectal Cancer Development and Progression in Mice Via Increasing Levels of IL6R and PAI1
Öner, M. G., Rokavec, M., Kaller, M., Bouznad, N., Horst, D. A., Kirchner, T., & Hermeking, H. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.08.011 · Cited by 50
Curcumin stabilizes p53 by interaction with NAD(P)H:quinone oxidoreductase 1 in tumor-derived cell lines
Patiño-Morales, C. C., Soto‐Reyes, E., Aréchaga-Ocampo, E., Ortíz-Sánchez, E., Antonio-Véjar, V., Pedraza‐Chaverrí, J., & García-Carrancá, A. M. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101320 · Cited by 49
Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell FormationPreprint
Shetzer, Y., Molchadsky, A., & Rotter, V. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026203 · Cited by 53
Respiratory Syncytial Virus Matrix Protein Induces Lung Epithelial Cell Cycle Arrest through a p53 Dependent Pathway
Bian, T., Gibbs, J. D., Örvell, C., & Imani, F. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038052 · Cited by 49
Activation of p53 pathway by Nutlin-3a inhibits the expression of the therapeutic target α5 integrin in colon cancer cells
Janoušková, H., Ray, A., Noulet, F., Lelong-Rebel, I. H., Choulier, L., Schaffner, F., Lehmann, M., Martin, S., Teisinger, J., & Dontenwill, M. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.03.018 · Cited by 49
Interrogation of MDM2 Phosphorylation in p53 Activation Using Native Chemical Ligation: The Functional Role of Ser17 Phosphorylation in MDM2 Reexamined
Zhan, C., Varney, K. M., Yuan, W., Zhao, L., & Lu, W. (2012) · Journal of the American Chemical Society · doi:10.1021/ja301255n · Cited by 50
Trp53 negatively regulates autoimmunity via the STAT3‐Th17 axis
Zhang, S., Zheng, M., Kibe, R., Huang, Y., Marrero, L., Warren, S., Zieske, A. W., Iwakuma, T., Kolls, J. K., & Cui, Y. R. (2011) · The FASEB Journal · doi:10.1096/fj.10-175299 · Cited by 48
Nickel accumulation in lung tissues is associated with increased risk of p53 mutation in lung cancer patients
Chiou, Y.-H., Wong, R., Chao, M., Chen, C., Liou, S., & Lee, H. (2014) · Environmental and Molecular Mutagenesis · doi:10.1002/em.21867 · Cited by 50
Boosting Natural Killer Cell-Based Immunotherapy with Anticancer Drugs: a Perspective
Cifaldi, L., Locatelli, F., Marasco, E., Moretta, L., & Pistoia, V. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.10.002 · Cited by 51
The Rich World of p53 DNA Binding Targets: The Role of DNA Structure
Brázda, V., & Fojta, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225605 · Cited by 56
Inflammation mediates the effect of discrimination, religiosity, and friendship network on expression of the Tp53 cancer suppressor gene
Simons, R. L., Lei, M., Carter, S. E., Beach, S. R. H., Gibbons, F. X., Gerrard, M., & Philibert, R. A. (2019) · SSM - Population Health · doi:10.1016/j.ssmph.2019.100389 · Cited by 50
Reprogramming aging and progeria
Freije, J. M., & López-Otín, C. (2012) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2012.08.009 · Cited by 46
A meta-analysis of cancer risk associated with the TP53 intron 3 duplication polymorphism (rs17878362): geographic and tumor-specific effects
Sagne, C., Marcel, V., Amadou, A., Hainaut, P. L., Olivier, M., & Hall, J. A. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.24 · Cited by 48
New Therapeutic Concept of NAD Redox Balance for Cisplatin Nephrotoxicity
Oh, G., Kim, H., Shen, A., Lee, S., Yang, S., Shim, H., Cho, E. Y., Kwon, K., Kwak, T. H., & So, H. (2016) · BioMed Research International · doi:10.1155/2016/4048390 · Cited by 48
microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis
Zhang, C., Liu, J., Tan, C., Yue, X., Zhao, Y., Peng, J., Wang, X., Laddha, S. V., Chan, C. S., Zheng, S. S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7088 · Cited by 49
Osthole inhibits proliferation of human breast cancer cells by inducing cell cycle arrest and apoptosis
Lintao, W., Peng, Y., Kaikai, S., Haixiao, W., Lü, J., Li, Y., & Ma, C. (2015) · Journal of Biomedical Research · doi:10.7555/jbr.27.20120115 · Cited by 48
Protopine isolated from Nandina domestica induces apoptosis and autophagy in colon cancer cells by stabilizing p53
Son, Y., An, Y., Jung, J., Shin, S., Park, I., Gwak, J., Ju, B. G., Chung, Y., Na, M., & Oh, S. (2019) · Phytotherapy Research · doi:10.1002/ptr.6357 · Cited by 48
The interplay between Epstein-Bar virus (EBV) with the p53 and its homologs during EBV associated malignancies
Chatterjee, K., Das, P., Chattopadhyay, N. R., Mal, S., & Choudhuri, T. (2019) · Heliyon · doi:10.1016/j.heliyon.2019.e02624 · Cited by 48
Discovery of the PTEN Tumor Suppressor and Its Connection to the PI3K and AKT OncogenesPreprint
Parsons, R. E. (2020) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a036129 · Cited by 48
A comparative study of CE‐SDS, SDS‐PAGE, and Simple Western—Precision, repeatability, and apparent molecular mass shifts by glycosylation
Scheller, C., Krebs, F., Wiesner, R., Wätzig, H., & Oltmann‐Norden, I. (2021) · Electrophoresis · doi:10.1002/elps.202100068 · Cited by 47
Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors
Park, H., Shapiro, G. I., Gao, X., Mahipal, A., Starr, J. S., Furqan, M., Singh, P. P., Ahrorov, A., Gandhi, L., Ghosh, A., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100573 · Cited by 47
Identification of TP53-induced glycolysis and apoptosis regulator (TIGAR) as the phosphoglycolate-independent 2,3-bisphosphoglycerate phosphatase
Gerin, I., Noël, G., Bolsée, J., Haumont, O., SCHAFTINGEN, E. V., & Bommer, G. T. (2014) · Biochemical Journal · doi:10.1042/bj20130841 · Cited by 48
Pharmacologic activation of wild-type p53 by nutlin therapy in childhood cancer
Maerken, T. V., Rihani, A., Goethem, A. V., Paepe, A. D., Speleman, F., & Vandesompele, J. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.11.002 · Cited by 47
The dominant-negative interplay between p53, p63 and p73: A family affair
Billant, O., Léon, A., Guellec, S. L., Friocourt, G., Blondel, M., & Voisset, C. (2016) · Oncotarget · doi:10.18632/oncotarget.11774 · Cited by 47
CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
Jiang, L., Ingelshed, K., Shen, Y., Boddul, S. V., Iyer, V. S., Kasza, Z., Sedimbi, S. K., Lane, D. P., & Wermeling, F. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1692 · Cited by 47
Avian Reovirus Protein p17 Functions as a Nucleoporin Tpr Suppressor Leading to Activation of p53, p21 and PTEN and Inactivation of PI3K/AKT/mTOR and ERK Signaling Pathways
Huang, W., Chiu, H., Liao, T., Chuang, K., Shih, W.-L., & Liu, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133699 · Cited by 47
The function of p53 and its role in Alzheimer’s and Parkinson’s disease compared to age-related macular degeneration
Wolfrum, P., Fietz, A., Schnichels, S., & Hurst, J. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.1029473 · Cited by 49
The anti-cancer agent APR-246 can activate several programmed cell death processes to kill malignant cells
Wang, Z., Hu, H., Heitink, L. S., Rogers, K. L., You, Y., Tan, T., Suen, C. S. N. L. W., Garnham, A. L., Chen, H., Lieschke, E., et al. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01122-3 · Cited by 55
β-catenin inhibitors in cancer therapeutics: intricacies and way forward
Dev, A. J. R., Vachher, M., & Prasad, C. P. (2023) · Bioengineered · doi:10.1080/21655979.2023.2251696 · Cited by 47
p53 attenuates AKT signaling by modulating membrane phospholipid composition
Rueda-Rincón, N., Bloch, K. M., Derua, R., Vyas, R., Harms, A. C., Hankemeier, T., Khan, N. A., Dehairs, J., Bagadi, M., Binda, M. M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4067 · Cited by 48
Is Survivin the Potential Achilles’ Heel of Cancer?
Lladser, Á., Sanhueza, C., Kiessling, R. W., & Quest, A. F. G. (2011) · Advances in cancer research · doi:10.1016/b978-0-12-385524-4.00001-5 · Cited by 45
Involvement of stromal p53 in tumor-stroma interactions
Bar, J., Moskovits, N. B.-C., & Oren, M. (2009) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2009.11.006 · Cited by 49
Self-citation
Activation of p53 with Ilimaquinone and Ethylsmenoquinone, Marine Sponge Metabolites, Induces Apoptosis and Autophagy in Colon Cancer Cells
Lee, H.-Y., Chung, K., Hwang, I., Gwak, J., Park, S., Ju, B. G., Yun, E., Kim, D., Chung, Y.-H., Na, M., et al. (2015) · Marine Drugs · doi:10.3390/md13010543 · Cited by 45
p53 is a major component of the transcriptional and apoptotic program regulated by PI 3-kinase/Akt/GSK3 signaling
Nayak, G., & Cooper, G. M. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.138 · Cited by 46
Targeting RING domains of Mdm2–MdmX E3 complex activates apoptotic arm of the p53 pathway in leukemia/lymphoma cells
Wu, W., Xu, C., Ling, X., Fan, C., Buckley, B., Chernov, M. V., Ellis, L., Li, F., Muñoz, I. G., & Wang, X. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.358 · Cited by 46
Regulation of myo-inositol biosynthesis by p53-ISYNA1 pathway
Koguchi, T., Tanikawa, C., Mori, J., Kojima, Y., & Matsuda, K. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3456 · Cited by 46
Pancreatic Cancer Progression Relies upon Mutant p53-Induced Oncogenic Signaling Mediated by NOP14
Du, Y., Liu, Z., You, L., Hou, P., Ren, X., Jiao, T., Zhao, W., Li, Z., Shu, H., Liu, C., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2339 · Cited by 46
Myeloid p53 regulates macrophage polarization and venous thrombus resolution by inflammatory vascular remodeling in mice
Mukhopadhyay, S., Antalis, T., Nguyen, K. P., Hoofnagle, M. H., & Sarkar, R. (2017) · Blood · doi:10.1182/blood-2016-07-727180 · Cited by 47
MicroRNA-1301 suppresses tumor cell migration and invasion by targeting the p53/UBE4B pathway in multiple human cancer cells
Wang, B., Wu, H., Chai, C., Lewis, J. D., Pichiorri, F., Eisenstat, D. D., Pomeroy, S. L., & Leng, R. P. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.04.038 · Cited by 46
Correlation of Ferroptosis and Other Types of Cell Death in Neurodegenerative Diseases
Dang, X., Huan, X., Du, X., Chen, X., Bi, M., Yan, C., Jiao, Q., & Jiang, H. F. (2022) · Neuroscience Bulletin · doi:10.1007/s12264-022-00861-6 · Cited by 46
Correction: Avian Reovirus Protein p17 Functions as a Nucleoporin Tpr Suppressor Leading to Activation of p53, p21 and PTEN and Inactivation of PI3K/AKT/mTOR and ERK Signaling Pathways
Huang, W., Chiu, H., Liao, T., Chuang, K., Shih, W.-L., & Liu, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138627 · Cited by 46
Microbeads mediated oral plasmid DNA delivery using polymethacrylate vectors: an effectual groundwork for colorectal cancer
Bhatt, P., Khatri, N., Kumar, M., Baradia, D., & Misra, A. R. (2014) · Drug Delivery · doi:10.3109/10717544.2014.898348 · Cited by 49
RETRACTED: Icariin as an emerging candidate drug for anticancer treatment: Current status and perspective
Liu, Y., Yang, H. K., Xiong, J., Zhao, J., Guo, M., Chen, J., Zhao, X., Chen, C., He, Z., Zhou, Y., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113991 · Cited by 45
Retracted
MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action
Somaiah, N., & Tap, W. D. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102668 · Cited by 45
Potential Therapeutic Targets in Uterine Sarcomas
Cuppens, T., Tuyaerts, S., & Amant, F. C. (2015) · Sarcoma · doi:10.1155/2015/243298 · Cited by 45
New perspective on targeting the tumor suppressor p53 pathway in the tumor microenvironment to enhance the efficacy of immunotherapy
Guo, G., & Cui, Y. R. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0053-5 · Cited by 47
Cell cycle kinetics, apoptosis rates, DNA damage and TP53 gene expression in bladder cancer cells treated with allyl isothiocyanate (mustard essential oil)
Sávio, A. L. V., da Silva, G. N., de Camargo, E. A., & Salvadori, D. M. F. (2014) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2014.02.006 · Cited by 45
Targeting the p53 Pathway
Golubovskaya, V., & Cance, W. G. (2013) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2013.06.003 · Cited by 45
Thymoma Patients Treated in a Phase I Clinic at MD Anderson Cancer Center: Responses to mTOR Inhibitors and Molecular Analyses
Wheler, J. J., Hong, D. S., Swisher, S. G., Falchook, G. S., Tsimberidou, A. M., Helgason, T., Naing, A., Stephen, B., Jankú, F., Stephens, P. J., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1015 · Cited by 45
RNA interference against TRIM29 inhibits migration and invasion of colorectal cancer cells
Xu, W., Xu, B., Yao, Y., Yu, X., Cao, H., Zhang, J., Liu, J., & Sheng, H. (2016) · Oncology Reports · doi:10.3892/or.2016.4941 · Cited by 45
Retracted
Nectin-3 is a new biomarker that mediates the upregulation of MMP2 and MMP9 in ovarian cancer cells
Xu, F., Si, X., Wang, J., Yang, A., Qin, T., & Yang, Y. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.11.020 · Cited by 45
Validation of Novel Prognostic Biomarkers for Early-Stage Clear-Cell, Endometrioid and Mucinous Ovarian Carcinomas Using Immunohistochemistry
Engqvist, H., Parris, T. Z., Kovács, A., Rönnerman, E. W., Sundfeldt, K., Karlsson, P., & Helou, K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00162 · Cited by 45
Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study
Koyama, T., Shimizu, T., Kojima, Y., Sudo, K., Okuma, H. S., Shimoi, T., Ichikawa, H., Kohsaka, S., Sadachi, R., Hirakawa, A., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0419 · Cited by 46
The Multifaceted Role of miR-21 in Pancreatic Cancers
Chen, C., Demirkhanyan, L. H., & Gondi, C. S. (2024) · Cells · doi:10.3390/cells13110948 · Cited by 48
Integrins and p53 pathways in glioblastoma resistance to temozolomide
Martin, S., Janoušková, H., & Dontenwill, M. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00157 · Cited by 43
Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL
Meijer, A., Kruyt, F. A. E., van der Zee, A. G. J., Hollema, H., Le, P., ten Hoor, K. A., Groothuis, G. M. M., Quax, W. J., de Vries, E. G. E., & de Jong, S. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.636 · Cited by 44
Chk1 and Wee1 control genotoxic-stress induced G2–M arrest in melanoma cells
Vera, J., Raatz, Y., Wolkenhauer, O., Kottek, T., Bhattacharya, A., Simon, J. C., & Kunz, M. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2015.01.020 · Cited by 44
From protein interaction networks to novel therapeutic strategies
Jaeger, S., & Aloy, P. (2012) · IUBMB Life · doi:10.1002/iub.1040 · Cited by 44
MicroRNAs as Key Effectors in the p53 Network
Goeman, F., Strano, S., & Blandino, G. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2017.04.003 · Cited by 44
Diverse p53/DNA binding modes expand the repertoire of p53 response elements
Vyas, P., Beno, I., Xi, Z., Stein, Y., Golovenko, D., Kessler, N., Rotter, V., Shakked, Z., & Haran, T. E. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1618005114 · Cited by 45
Observation of acetyl phosphate formation in mammalian mitochondria using real-time in-organelle NMR metabolomics
Xu, W. J., Wen, H., Kim, H. S., Ko, Y., Dong, S.-M., Park, I.-S., Yook, J. I., & Park, S. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720908115 · Cited by 43

Authors: Levine, A. J., & Oren, M.
Affiliations: Institute for Advanced Study (US)
Weizmann Institute of Science (IL)
ORCID: Levine, Arnold J.
Oren, Moshe
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2009-10
Volume: 9
Issue: 10
Pages: 749-758
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/nrc2723
PMC: PMC2771725
OpenAlex: W1966163762
Cited by: 1,967
References: 169
Citations by year: 2026: 64 · 2025: 111 · 2024: 107 · 2023: 112 · 2022: 114 · 2021: 129 · 2020: 128 · 2019: 111 · 2018: 127 · 2017: 120 · 2016: 144 · 2015: 115 · 2014: 150 · 2013: 113 · 2012: 170
FWCI: 9.34
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (P01CA087497, R37 CA40099, R37CA040099, P01CA87497.)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords: p53, TP53, tumour suppressor, SV40 large T antigen, transcription factors, cell cycle arrest, apoptosis, cellular senescence, metabolic regulation, cytokine regulation, embryo implantation
MeSH terms: Animals, Humans, Neoplasms, Genes, p53, Tumor Suppressor Protein p53, History, 20th Century, History, 21st Century

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The first 30 years of p53: growing ever more complex.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks